310 related articles for article (PubMed ID: 11704811)
1. Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines.
Withoff S; Glazenburg KL; van Veen ML; Kraak MM; Hospers GA; Störkel S; de Vries EG; Wilschut J; Daemen T
Gene Ther; 2001 Oct; 8(20):1515-23. PubMed ID: 11704811
[TBL] [Abstract][Full Text] [Related]
2. Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF.
Klimp AH; van der Vaart E; Lansink PO; Withoff S; de Vries EG; Scherphof GL; Wilschut J; Daemen T
Gene Ther; 2001 Feb; 8(4):300-7. PubMed ID: 11313804
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
5. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy.
Parkinson RJ; Mian S; Bishop MC; Gray T; Li G; McArdle SE; Ali S; Rees RC
Prostate; 2003 Jun; 56(1):65-73. PubMed ID: 12746848
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of ovarian cancer cells transduced by the bicistronic retroviral vector containing GM-CSF and HSV-TK genes.
Guan J; Ma L; Wei L
Chin Med J (Engl); 2001 Feb; 114(2):147-51. PubMed ID: 11780195
[TBL] [Abstract][Full Text] [Related]
7. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.
Kim SH; Carew JF; Kooby DA; Shields J; Entwisle C; Patel S; Shah JP; Fong Y
Cancer Gene Ther; 2000 Sep; 7(9):1279-85. PubMed ID: 11023201
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
9. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
10. Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model.
Tanaka K; Towata S; Nakao K; Mizuguchi H; Hayakawa T; Niwa M; Ishii N; Nagayama Y
Clin Endocrinol (Oxf); 2003 Dec; 59(6):734-42. PubMed ID: 14974915
[TBL] [Abstract][Full Text] [Related]
11. [Recombinant human GM-CSF retroviral vector construction and expression in human breast cancer cells].
Zhao M; Mao N; Ba D
Zhonghua Zhong Liu Za Zhi; 1997 Jan; 19(1):42-4. PubMed ID: 10743054
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
Shi FS; Weber S; Gan J; Rakhmilevich AL; Mahvi DM
Cancer Gene Ther; 1999; 6(1):81-8. PubMed ID: 10078967
[TBL] [Abstract][Full Text] [Related]
13. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.
Toda M; Martuza RL; Rabkin SD
Mol Ther; 2000 Oct; 2(4):324-9. PubMed ID: 11020347
[TBL] [Abstract][Full Text] [Related]
14. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
Tai KF; Chen PJ; Chen DS; Hwang LH
J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
Wang L; Qi X; Sun Y; Liang L; Ju D
Cancer Gene Ther; 2002 Oct; 9(10):819-24. PubMed ID: 12224022
[TBL] [Abstract][Full Text] [Related]
16. Genetically engineered tumor cell vaccine in a head and neck cancer model.
Couch M; Saunders JK; O'Malley BW; Pardoll D; Jaffee E
Laryngoscope; 2003 Mar; 113(3):552-6. PubMed ID: 12616213
[TBL] [Abstract][Full Text] [Related]
17. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
18. Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins.
Whittington HA; Ashworth LJ; Hawkins RE
Gene Ther; 1998 Jun; 5(6):770-7. PubMed ID: 9747457
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
[TBL] [Abstract][Full Text] [Related]
20. Systemic genetic transfer of p21WAF-1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex.
Liu X; Tian PK; Ju DW; Zhang MH; Yao M; Cao XT; Gu JR
Cancer Gene Ther; 2003 Jul; 10(7):529-39. PubMed ID: 12833133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
